CN Mobile Logo



Some Sarcomas May Require Long-Term Follow-Up

Although rare, long-term recurrence of soft-tissue sarcoma is possible, and patients with retroperitoneal, very large sarcomas, or high-grade disease should undergo long-term follow-up to detect late disease recurrence.


Trabectedin was found to offer superior disease control to dacarbazine in patients with advanced liposarcoma and leiomyosarcoma.

Preoperative chemotherapy, both with or without concurrent radiotherapy, is feasible among patients with localized, high-risk soft-tissue sarcoma, according to a new phase III trial.

Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.

A retrospective study was used to develop nomograms predictive of both metastasis-free and overall survival for patients with nonmetastatic osteosarcoma.

In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.

Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.

In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.


Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.